Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 1,536,287 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Addex Therapeutics?
Among the largest hedge funds holding Addex Therapeutics’s share is New Leaf Venture Partners, L.L.C.. It holds Addex Therapeutics’s shares valued at N/A.
Addex Therapeutics Ltd is a biopharmaceutical company. The company operates through single segment which includes developing drugs to improve human health. It is focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. In addition, it is also engaged in the development of the dipraglurant and ADX71441 program. The company's geographical area of operations includes Switzerland and Europe.